A call for more integrated cardiovascular safety assessment

Journal of Pharmacological and Toxicological Methods

Volumn 61, Issue 1, 2010, Pages 1-2

  Pettit, S D ^a   Berridge, B ^b   Sarazan, R D ^c  

^a ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c 206 Carnegie Center   (United States)

Author keywords

Cardiovascular safety; Consortia; Drug development

Indexed keywords

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONSENSUS DEVELOPMENT; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GOOD CLINICAL PRACTICE; HEART HEMODYNAMICS; HUMAN; INOTROPISM; NONHUMAN; PATIENT ASSESSMENT; PATIENT SAFETY; RISK ASSESSMENT;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; RISK ASSESSMENT;

EID: 72149133378     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.08.001     Document Type: Article

References (1)

1. Lasser K.E., Allen P.D., Woolhandler S.J., Himmelstein D.U., Wolfe S.M., and Bor D.H. Timing of new black box warnings and withdrawals for prescription medications. Journal of the American Medical Association 287 (2002) 2215-2220